Michael Exton, the new CEO of Lexicon Pharmaceuticals, is steering the company through significant changes after recognizing that its current operations were not sustainable. Just three weeks into his role, Exton proposed closing commercial operations to refocus on research and development. His experience at Novartis, where he helped turn around the heart failure drug Entresto, informed his belief that Lexicon’s remaining approved drug, Inpefa, would struggle to achieve its potential due to market competition and insurance hurdles. Exton’s strategy involved tough decisions, including reducing the workforce from 250 to 90 and restructuring company debt.

For people interested in longevity and health, Lexicon’s focus on developing innovative treatments could lead to new options for managing chronic conditions. Inpefa, which aims to reduce heart failure risk, is currently in a phase 3 trial for a specific heart condition, with results expected in early 2027. Additionally, the company is exploring a new pain treatment, pilavapadin, which could address diabetic peripheral neuropathic pain, a condition affecting millions of Americans. If successful, these developments could provide alternatives to traditional pain management methods, such as opioids, which carry significant risks.

While the company has faced setbacks, including a failed FDA approval for Inpefa as a diabetes treatment, Exton remains optimistic. Lexicon has secured a lucrative licensing deal with Novo Nordisk for another candidate, LX9851, and is preparing to resubmit Inpefa for diabetes approval. This renewed focus on R&D may lead to breakthroughs that improve health outcomes for people with chronic conditions, making it a company to watch in the coming years.

Source: fiercebiotech.com